THE ARISING · Longevity & Healthspan
Lactoferrin Has Plausible Anti-Aging Mechanisms but Little Outcome Data, Review Finds
Lactoferrin, a protein found in milk and sold as a supplement, touches several systems that decline with age. A new review asks whether that adds up to healthier aging in people. So far, the answer rests mostly on lab and animal work.
The paper is a narrative review in Nutrients (2026) by Evans, Naddafha and Peterson. It does not report a new trial. The authors searched PubMed, Google Scholar and Scopus and sorted the evidence into four types: direct human evidence in older adults, human evidence from younger or disease-specific groups, animal studies, and cell or tissue experiments. They write that evidence of lactoferrin's effect on healthy aging "remains limited."
Lactoferrin is an iron-binding protein with two lobes, each able to hold one iron ion. The body makes it in epithelial cells, and it is found in saliva, tears and digestive fluids. The review notes that human and bovine versions differ in amino acid sequence and sugar attachments, which may change how they act.
The authors focus on four areas tied to aging: the gut and its microbes, immune regulation and inflammation, iron balance, and mitochondrial function with oxidative stress. Aging brings a decline in microbes that make short-chain fatty acids, a leakier gut lining and persistent low-grade inflammation, sometimes called inflammaging.
In the gut, the review describes lactoferrin as promoting growth and specialization of the cells lining the intestine. It strengthens tight junction proteins and lowers permeability. In cell studies, the iron-free form of lactoferrin altered NF-κB and PPAR-γ signaling in intestinal cells, which reduced inflammatory cytokine production.
Lactoferrin also appears to shape which microbes thrive. Because it binds iron tightly, it limits the iron available to harmful bacteria. Various preparations were active against E. coli while promoting Lactobacillus and Bifidobacterium species. According to the review, the effect depends on dose: lower concentrations supported helpful bacteria, and higher ones acted against microbes.
Some of the microbiome evidence comes from people. In a human study, recombinant human lactoferrin maintained microbial diversity, enriched beneficial groups and changed short-chain fatty acid production, though not in an elderly group. In older adults, bovine lactoferrin was associated with greater microbial diversity and more beneficial taxa. The authors add that shifts in bacterial abundance do not by themselves confer health benefits, and they call for studies that measure function.
Beyond the gut, the review says lactoferrin may support mitochondrial function and redox balance. Much of this evidence is preclinical. Early human studies show improvements in inflammatory and iron-related biomarkers.
On safety, the review says lactoferrin has been well tolerated in human trials, with no meaningful rise in adverse effects. It has U.S. Food and Drug Administration "generally recognized as safe" status, but the authors stress that this applies to specific sources, formulations and uses, not every lactoferrin product. That food-use status does not establish anti-ageing efficacy.
The review notes that some emerging findings are company-associated or come from preprints and have not been independently replicated. Whether biomarker changes translate into better function in older adults remains to be established.
The authors call for well-designed trials in older adults that measure functional outcomes, cardiometabolic health, immune resilience and markers of biological aging. Results from such trials will show whether lactoferrin's biological activity amounts to a real benefit.